美国威斯康星医学院癌症方向博后职位招聘

An excellent training opportunity for junior/senior post-doctoral fellows is available in a dynamic cancer research laboratory of Dr. Marja Nevalainen. The candidate will investigate Jak-Stat signaling in prostate/pancreatic cancer diagnostics, progression and therapy, and how Jak-Stat signaling promotes cancer progression to therapy resistant metastatic disease using human specimens as well as PDX and cell culture models. One area of current focus is on Stat5 regulation of DNA repair in prostate cancer. Marja Nevalainen’s group provided the proof-of-concept that Stat5 is a therapeutic target protein for prostate cancer. Her group demonstrated that Stat5 controls prostate cancer cell viability and castrate-resistant prostate tumor growth, and Jak2-Stat5a/b signaling induces simultaneously epithelial- mesenchymal transition and stem cell-like properties in prostate cancer cells. Dr. Nevalainen lab further discovered that the Stat5 locus is amplified in castrate-resistant and metastatic prostate cancer, followed by an important translational finding that elevated active Stat5 in prostate cancer prior to intent-to-cure radical prostatectomy predicts development of castrate-resistant and metastatic spread of the disease in patients. The Nevalainen laboratory recently identified a family of novel small molecule Stat5 inhibitors with high efficacy in both prostate cancer and Bcr-Abl-driven leukemias. Current work on pancreatic cancer is focused on development of a test system to predict responsiveness of clinical pancreatic cancer to different available pharmacological therapies to assist the selection of an optimal therapy. This postdoctoral training position includes a strong support from the mentor for career development toward an independent investigator status.